Although many epidemiologists use the National Death Index (NDI) as the "gold standard" for ascertainment of US mortality, high search costs per year and per subject for large cohorts warrant consideration of less costly alternatives. In this study, for 1995-2001 deaths, the authors compared matches of a random sample of 11,968 National Institutes of Health (NIH)-AARP Diet and Health Study subjects to the Social Security Administration's Death Master File (DMF) and commercial list updates (CLU) with matches of those subjects to the NDI. They examined how varying the lower limits of estimated DMF match probabilities (m scores of 0.60, 0.20, and 0.05) altered the benefits and costs of mortality ascertainment. Observed DMF/CLU ascertainment of NDI-identified decedents increased from 89.8% to 95.1% as m decreased from 0.60 (stringent) to 0.20 (less stringent) and increased further to 96.4% as m decreased to 0.05 (least stringent). At these same cutpoints, the false-match probability increased from 0.4% of the sample to 0.6% and then 2.3%. Limiting NDI cause-of-death searches to subjects found in DMF searches using less stringent match criteria, further supplemented by CLU vital status updates, improves vital status assessment while increasing substantially the cost-effectiveness of ascertaining mortality in large prospective cohort studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732974 | PMC |
http://dx.doi.org/10.1093/aje/kwn404 | DOI Listing |
JMIR Res Protoc
January 2025
National Radiotherapy, Oncology and Nuclear Medicine Centre, Korle-bu Teaching Hospital, Accra, Ghana.
Background: Cancer is a leading cause of global mortality, accounting for nearly 10 million deaths in 2020. This is projected to increase by more than 60% by 2040, particularly in low- and middle-income countries. Yet, palliative and psychosocial oncology care is very limited in these countries.
View Article and Find Full Text PDFJ Med Internet Res
January 2025
Department of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, The Second Xiangya Hospital of Central South University, Changsha, China.
Background: Acute kidney injury (AKI) is a common complication in hospitalized older patients, associated with increased morbidity, mortality, and health care costs. Major adverse kidney events within 30 days (MAKE30), a composite of death, new renal replacement therapy, or persistent renal dysfunction, has been recommended as a patient-centered endpoint for clinical trials involving AKI.
Objective: This study aimed to develop and validate a machine learning-based model to predict MAKE30 in hospitalized older patients with AKI.
JCO Glob Oncol
January 2025
Auckland Regional Cancer and Blood Service, Te Toka Tumai Auckland, Health New Zealand, Te Whatu Ora, Auckland, New Zealand.
Purpose: In Aotearoa New Zealand, there are inequitable outcomes for Pacific peoples who experience higher rates of preventable cancers and poorer survival compared with other ethnicities. The aim of this study was to explore Pacific peoples lived experience of cancer and its treatment in the Auckland setting.
Methods: Data were collected through semistructured interviews (talanoa) with Pacific patients under the Auckland Regional Cancer and Blood Service.
Sci Immunol
January 2025
Department of Cell and Developmental Biology, School of Biological Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Mechanistic understanding of the inhibitory immunoreceptor PD-1 is largely based on mouse models, but human and mouse PD-1 share only 59.6% amino acid identity. Here, we found that human PD-1 is more inhibitory than mouse PD-1, owing to stronger interactions with the ligands PD-L1 and PD-L2 and more efficient recruitment of the effector phosphatase Shp2.
View Article and Find Full Text PDFPLoS One
January 2025
Colorectal Cancer Center, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
This study aimed to identify radiotherapy dosimetric parameters related to local failure (LF)-free survival (LFFS) in patients with lung and liver oligometastases from colorectal cancer treated with stereotactic body radiotherapy (SBRT). We analyzed 75 oligometastatic lesions in 55 patients treated with SBRT between January 2014 and December 2021. There was no constraint or intentional increase in maximum dose.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!